Fluzinamide (AHR-8559) has anticonvulsant effects on ignited amygdala seizures.

Extensively metabolized in mice, rats, and dogs, Fluzinamide, an antiepileptic agent effective against partial seizures, has its anticonvulsant properties evaluated in the kindled amygdaloid seizure model in rats. At doses that do not cause sedation or ataxia, Fluzinamide significantly attenuates afterdischarge durations and the severity of accompanying convulsive responses in previously kindled rats. The maximum anticonvulsant effectiveness against suprathreshold (400 μA) stimulation is observed at 30 min after acute intraperitoneal injections. Additionally, Fluzinamide (10-80 mg/kg i.p.) is assessed in kindled rats using threshold (20 μA increments) seizures. Low doses of Fluzinamide significantly elevate seizure threshold and reduce both elicited after-discharge durations and seizure severity. Administered daily during kindling acquisition, Fluzinamide (20 and 40 mg/kg i.p.) significantly increases the number of trials necessary to complete kindling. The duration and severity of responses induced by stimulations during the acquisition period are reduced [1].